MRSN - Mersana Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
Enterprise Value 3
Trailing P/E
Forward P/E 1
PEG Ratio (5 yr expected) 1
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue 3
Enterprise Value/EBITDA 6

Trading Information

Stock Price History

Beta (5Y Monthly) 2.30
52-Week Change 3113.76%
S&P500 52-Week Change 325.98%
52 Week High 38.93
52 Week Low 31.32
50-Day Moving Average 35.00
200-Day Moving Average 33.16

Share Statistics

Avg Vol (3 month) 3368.01k
Avg Vol (10 day) 3831.38k
Shares Outstanding 545.31M
Float 24.54M
% Held by Insiders 1N/A
% Held by Institutions 1N/A
Shares Short (Dec 30, 2019) 41.07M
Short Ratio (Dec 30, 2019) 43.07
Short % of Float (Dec 30, 2019) 44.53%
Short % of Shares Outstanding (Dec 30, 2019) 42.37%
Shares Short (prior month Nov 28, 2019) 4724.84k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019


Profit Margin -79.49%
Operating Margin (ttm)-84.08%

Management Effectiveness

Return on Assets (ttm)-21.05%
Return on Equity (ttm)-55.97%

Income Statement

Revenue (ttm)43.27M
Revenue Per Share (ttm)1.16
Quarterly Revenue Growth (yoy)-60.80%
Gross Profit (ttm)-49.32M
EBITDA -35.07M
Net Income Avi to Common (ttm)-34.39M
Diluted EPS (ttm)-0.92
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)112M
Total Cash Per Share (mrq)2.34
Total Debt (mrq)8.62M
Total Debt/Equity (mrq)9.27
Current Ratio (mrq)5.12
Book Value Per Share (mrq)1.94

Cash Flow Statement

Operating Cash Flow (ttm)-71.07M
Levered Free Cash Flow (ttm)-27.82M